Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence
- PMID: 12928471
- DOI: 10.1001/jama.290.7.932
Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence
Abstract
Context: Atherosclerotic vascular disease is an enormous public health problem. A number of emerging risk factors for atherosclerosis have recently been proposed to help identify high-risk individuals.
Objective: To review the epidemiological, basic science, and clinical trial evidence concerning 4 emerging risk factors: C-reactive protein, lipoprotein(a), fibrinogen, and homocysteine.
Data sources: Using the terms atherosclerosis, cardiovascular disease, risk factors, prevention, screening, C-reactive protein, lipoprotein(a), fibrinogen, and homocysteine, we searched the MEDLINE database from January 1990 to January 2003. Conference proceedings, abstract booklets, bibliographies of pertinent articles and books, and personal files were hand searched to identify additional articles.
Study selection: Original investigations and reviews of the epidemiology of atherosclerosis and the association of conventional and novel risk factors with vascular risk were selected. On the basis of the search strategy, 373 relevant studies were identified.
Data extraction: A diverse array of studies were examined, including randomized controlled trials, prospective cohort studies, systematic overviews, case-control, cross-sectional, and mechanistic studies. Data extraction was performed by one of the authors.
Data synthesis: The available epidemiological and basic science evidence supports, to varying degrees, independent associations between these 4 candidate risk factors and atherosclerotic vascular disease. However, there is relatively little data regarding the additive yield of screening for these factors over that of validated global risk assessment strategies currently in use. Furthermore, controlled intervention studies targeting individuals with these factors for proven risk-reduction therapies, or specifically treating these factors with available therapies, are few. The explanatory power of the major, established cardiovascular risk factors has been systematically underestimated.
Conclusions: Although C-reactive protein, lipoprotein(a), fibrinogen, and homocysteine are associated with vascular disease risk, their optimal use in routine screening and risk stratification remains to be determined.
Comment in
-
Major risk factors for cardiovascular disease: debunking the "only 50%" myth.JAMA. 2003 Aug 20;290(7):947-9. doi: 10.1001/jama.290.7.947. JAMA. 2003. PMID: 12928473 No abstract available.
-
Novel risk factors for atherosclerosis.JAMA. 2004 Jan 21;291(3):301; author reply 301-2. doi: 10.1001/jama.291.3.301-b. JAMA. 2004. PMID: 14734584 No abstract available.
-
Novel risk factors for atherosclerosis.JAMA. 2004 Jan 21;291(3):301; author reply 301-2. doi: 10.1001/jama.291.3.301-a. JAMA. 2004. PMID: 14734585 No abstract available.
-
Conventional risk factors and cardiac events--debunking an old myth about prevalence.Rev Cardiovasc Med. 2004 Summer;5(3):185-6. Rev Cardiovasc Med. 2004. PMID: 15346104 No abstract available.
-
History of emerging vascular disease risk factors.JAMA. 2004 Nov 3;292(17):2086; author reply 2086. doi: 10.1001/jama.292.17.2086-b. JAMA. 2004. PMID: 15523068 No abstract available.
Similar articles
-
Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease.JAMA. 2001 May 16;285(19):2481-5. doi: 10.1001/jama.285.19.2481. JAMA. 2001. PMID: 11368701
-
[Homocysteine--CRP--lipoprotein (a). When do you evaluate the "new" risk factors].MMW Fortschr Med. 2001 Jan 25;143(4):22-4. MMW Fortschr Med. 2001. PMID: 11219276 German.
-
Novel risk factors for atherosclerosis.Mayo Clin Proc. 2000 Apr;75(4):369-80. doi: 10.4065/75.4.369. Mayo Clin Proc. 2000. PMID: 10761492 Review.
-
Conditional risk factors for atherosclerosis.Mayo Clin Proc. 2005 Feb;80(2):219-30. doi: 10.4065/80.2.219. Mayo Clin Proc. 2005. PMID: 15704777 Review.
-
The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study.Metabolism. 2005 Sep;54(9):1236-42. doi: 10.1016/j.metabol.2005.04.010. Metabolism. 2005. PMID: 16125536 Clinical Trial.
Cited by
-
[Primary prevention of cardiovascular diseases. Stepchild of internal medicine].Internist (Berl). 2004 Feb;45(2):173-81. doi: 10.1007/s00108-003-1130-2. Internist (Berl). 2004. PMID: 14991159 German.
-
The Interleukin-6 inflammation pathway from cholesterol to aging--role of statins, bisphosphonates and plant polyphenols in aging and age-related diseases.Immun Ageing. 2007 Mar 20;4:1. doi: 10.1186/1742-4933-4-1. Immun Ageing. 2007. PMID: 17374166 Free PMC article.
-
Effect of periodontal treatment in patients with periodontitis and diabetes: systematic review and meta-analysis.J Appl Oral Sci. 2020 Jan 10;28:e20190248. doi: 10.1590/1678-7757-2019-0248. eCollection 2020. J Appl Oral Sci. 2020. PMID: 31939522 Free PMC article.
-
The Relationship Between Admission Insulin Resistance Index (AIRI) and In-Hospital Outcome in Non-Diabetic Acute Coronary Syndrome.J ASEAN Fed Endocr Soc. 2023;38(1):7-12. doi: 10.15605/jafes.038.01.03. Epub 2023 Feb 8. J ASEAN Fed Endocr Soc. 2023. PMID: 37252423 Free PMC article.
-
Early identification of cardiovascular risk using genomics and proteomics.Nat Rev Cardiol. 2010 Jun;7(6):309-17. doi: 10.1038/nrcardio.2010.53. Epub 2010 May 4. Nat Rev Cardiol. 2010. PMID: 20440292 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials